fingolimod hydrochloride has been researched along with Diffuse Large B-Cell Lymphoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fan, G; Hopkins, RS; Kim, E; Okada, CY; White, KP; Wills, A | 1 |
| Armstrong, B; Deng, J; Forman, S; Kowolik, C; Lee, H; Liu, Y; Scuto, A; Wang, L; Weiss, LM; Yu, H | 1 |
2 other study(ies) available for fingolimod hydrochloride and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
Primary cutaneous Epstein-Barr virus-positive diffuse large B-cell lymphoma (DLBCL) in a patient taking fingolimod.
Topics: Biopsy; Epstein-Barr Virus Infections; Fingolimod Hydrochloride; Herpesvirus 4, Human; Humans; In Situ Hybridization; Lymphocytes; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; RNA, Viral; Skin; Skin Diseases, Viral; Sphingosine 1 Phosphate Receptor Modulators | 2019 |
S1PR1 is an effective target to block STAT3 signaling in activated B cell-like diffuse large B-cell lymphoma.
Topics: Animals; Apoptosis; B-Lymphocytes; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Fingolimod Hydrochloride; Gene Silencing; Humans; Lymphocyte Activation; Lymphoma, Large B-Cell, Diffuse; Mice; Neoplasm Invasiveness; Phosphorylation; Propylene Glycols; Receptors, Lysosphingolipid; RNA, Small Interfering; Signal Transduction; Sphingosine; Sphingosine-1-Phosphate Receptors; STAT3 Transcription Factor | 2012 |